Jade Biosciences, Inc. Severance Costs
Jade Biosciences, Inc. (JBIO) reported Severance Costs of $2.60 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2024-08-12
- Jade Biosciences, Inc. severance costs for the quarter ending 2024-06-30 was $2.60M.
| Period end | Severance Costs 3 month |
|---|---|
| 2024-06-30 | $2.60M 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |